Semaglutide and tirzepatide represent new treatment modalities in type 2 diabetes mellitus (T2DM) and obesity and increase the range of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.